Previous Close | 3.2000 |
Open | 3.2200 |
Bid | 2.9300 x 1400 |
Ask | 2.9600 x 4000 |
Day's Range | 2.8500 - 3.2300 |
52 Week Range | 0.4900 - 3.4300 |
Volume | |
Avg. Volume | 11,132,531 |
Market Cap | 581.825M |
Beta (5Y Monthly) | 1.17 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.3610 |
Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.87 |
Subscribe to Yahoo Finance Plus to view Fair Value for ARDX
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.
Having gambled in under-the-radar penny stocks myself, I can tell you firsthand, the outcome hasn’t always been great. There are a lot of risks involved, so tread lightly. Many experts will advise you to steer clear of penny stocks – and for good reason. Oftentimes, they’ll tempt speculative traders with the idea of easy growth, and the opportunity to double, triple, or even quintuple returns in no time. Many of you don’t need me to lecture you on penny stocks. I’m sure some of you have learned